date:Aug 01, 2018
regulatory expertise said they would anticipate strong opposition from GW Pharmaceuticals.
The company intends to bring its CBD medicine to the U.S. market through its subsidiary, Greenwich Biosciences Inc., following an anticipated scheduling action by DEA.
Daniel Fabricant, Ph.D., previously led FDAs Division of Dietary Supplement Programs and is the CEO and president of the Natural Products Association (NPA).
He discussed two theoretical petitions filed with the HHS Secretary: a petition c